Alternative pathway therapy for urea cycle disorders: twenty years later
- PMID: 11148549
- DOI: 10.1067/mpd.2001.111836
Alternative pathway therapy for urea cycle disorders: twenty years later
Erratum in
- J Pediatr 2002 Apr;140(4):490
Abstract
Alternative pathway therapy is currently an accepted treatment approach for inborn errors of the urea cycle. This involves the long-term use of oral sodium phenylbutyrate, arginine supplements, or both, depending on the specific enzyme deficiency, and treatment of acute hyperammonemic crises with intravenous sodium benzoate/sodium phenylacetate plus arginine. A review of 20 years of experience with this approach illustrates the strengths and limitations of this treatment. It has clearly decreased the mortality and morbidity from these disorders, but they remain unacceptably high. The medications are generally well tolerated, but severe accidental overdosage has been reported because of the infrequent use of the medication. There is also a difference in their metabolism between newborns and older children that must be addressed in determining dosage. To avoid these complications it is recommended that drug levels in blood be monitored routinely and that very specific treatment protocols and oversight be followed to avoid overdoses. Finally, it must be acknowledged that alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. Therefore in children with neonatal-onset disease or in those with very poor metabolic control, liver transplantation should be considered. There should also be the continued search for innovative therapies that may offer a more permanent and complete correction, such as gene therapy.
Similar articles
-
Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.N Engl J Med. 2007 May 31;356(22):2282-92. doi: 10.1056/NEJMoa066596. N Engl J Med. 2007. PMID: 17538087 Clinical Trial.
-
Alternative-pathway therapy for hyperammonemia.N Engl J Med. 2007 May 31;356(22):2321-2. doi: 10.1056/NEJMe078075. N Engl J Med. 2007. PMID: 17538092 No abstract available.
-
Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients.Mol Genet Metab. 2004 Apr;81 Suppl 1:S79-85. doi: 10.1016/j.ymgme.2003.11.017. Mol Genet Metab. 2004. PMID: 15050979
-
Argininosuccinate lyase deficiency.Genet Med. 2012 May;14(5):501-7. doi: 10.1038/gim.2011.1. Epub 2012 Jan 5. Genet Med. 2012. PMID: 22241104 Free PMC article. Review.
-
Treatment of urea cycle disorders.Enzyme. 1987;38(1-4):242-50. doi: 10.1159/000469211. Enzyme. 1987. PMID: 3326732 Review.
Cited by
-
Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.BMC Gastroenterol. 2022 Mar 28;22(1):144. doi: 10.1186/s12876-022-02213-0. BMC Gastroenterol. 2022. PMID: 35346058 Free PMC article.
-
Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy.BMC Infect Dis. 2018 Jul 4;18(1):303. doi: 10.1186/s12879-018-3203-9. BMC Infect Dis. 2018. PMID: 29973153 Free PMC article.
-
A zebrafish model of hyperammonemia.Mol Genet Metab. 2014 Sep-Oct;113(1-2):142-7. doi: 10.1016/j.ymgme.2014.07.001. Epub 2014 Jul 10. Mol Genet Metab. 2014. PMID: 25069822 Free PMC article.
-
Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.Sci Rep. 2017 May 10;7(1):1711. doi: 10.1038/s41598-017-01861-7. Sci Rep. 2017. PMID: 28490733 Free PMC article.
-
An Intriguing Case of Acute Encephalopathy: Lesson Learned from a Constipated Man.Cureus. 2020 Jan 16;12(1):e6678. doi: 10.7759/cureus.6678. Cureus. 2020. PMID: 32104618 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical